Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant acinetobacter spp.

Microbial Drug Resistance

Volumn 18, Issue 6, 2012, Pages 562-566

  Moon, Soo Youn ^a,b   Peck, Kyong Ran ^a   Chang, Hyun Ha ^c   Kim, Shin Woo ^c   Heo, Sang Taek ^d   Son, Jun Seong ^b   Ryu, Seong Yeol ^e   Moon, Chisook ^f   Jung, Sook In ^g   Shin, Sang Yop ^h   Lee, Jeong A ^a   Joung, Mi Kyong ^a   Chung, Doo Ryeon ^a   Kang, Cheol In ^a   Song, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Gyeongsang National University   (South Korea)

^e Dongsan Medical Center   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Chonnam National University Medical School   (South Korea)

^h Jeju National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGED; ARTICLE; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; SUPERINFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; COINFECTION; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL RATE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; PSEUDOMONAS AERUGINOSA;

EID: 84869471805     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2012.0010     Document Type: Article

References (26)

1. Anthony, K.B., N.O. Fishman, D.R. Linkin, L.B. Gasink, P.H. Edelstein, and E. Lautenbach. 2008. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46:567-570.
2. Bassetti, M., L.Nicolini, E. Repetto, E. Righi, V. Del Bono, and C. Viscoli. 2010. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect. Dis. 10:287.
3. Bone, R.C., R.A. Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, W.A. Knaus, R.M. Schein, and W.J. Sibbald. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
4. Chan, J.D., J.A. Graves, and T.H. Dellit. 2010. Antimicrobial treatment and clinical outcomes of carbapenemresistant Acinetobacter baumannii ventilator-associated pneumonia. J. Intensive Care Med. 25:343-348.
5. Chemaly, R.F., S.S. Hanmod, Y. Jiang, D.B. Rathod, V. Mulanovich, J.A. Adachi, K.V. Rolston, I.I. Raad, and R.Y. Hachem. 2009. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 88:211-220.
6. Curcio, D., J. Castagnino, W. Vazquez, G. Vergara, and A. Curiale. 2010. Tigecycline in the treatment of ventilatorassociated pneumonia: experience from the Latin American Tigecycline Use Registry. Infez Med. 18:27-34.
7. Curcio, D., F. Fernandez, J. Vergara, W. Vazquez, and C.M. Luna. 2009. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J. Chemother. 21:58-62.
8. Deyo, R.A., D.C. Cherkin, and M.A. Ciol. 1992. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45:613-619.
9. Falagas, M.E., and D.E. Karageorgopoulos. 2008. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin. Infect. Dis. 46:1121-1122; author reply 1122.
10. Fishbain, J., and A.Y. Peleg. 2010. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51:79-84.
11. Freire, A.T., V. Melnyk, M.J. Kim, O. Datsenko, O. Dzyublik, F. Glumcher, Y.C. Chuang, R.T. Maroko, G. Dukart, C.A. Cooper, J.M. Korth-Bradley, N. Dartois, and H. Gandjini. 2010. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 68:140-151.
12. Friedman, N.D., K.S. Kaye, J.E. Stout, S.A. McGarry, S.L. Trivette, J.P. Briggs, W. Lamm, C. Clark, J. MacFarquhar, A.L. Walton, L.B. Reller, and D.J. Sexton. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137:791-797.
13. Garcia-Cabrera, E., M.E. Jimenez-Mejias, M.V. Gil Navarro, M.J. Gomez-Gomez, C. Ortiz-Leyba, E. Cordero, and J. Pachon. 2010. Superinfection during treatment of nosocomial infections with tigecycline. Eur. J. Clin. Microbiol. Infect. Dis. 29:867-871.
14. Gardiner, D., G. Dukart, A. Cooper, and T. Babinchak. 2010. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin. Infect. Dis. 50:229-238.
15. Gordon, N.C., and D.W.Wareham. 2009. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother. 63:775-780.
16. Hoban, D.J., S.K. Bouchillon, B.M. Johnson, J.L. Johnson, and M.J. Dowzicky. 2005. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52:215-227.
17. Tigecycline labeling. Available at: www.accessdata.fda.gov/drugsatfda- docs/label/2010/021821s027lbl.pdf. (last accessed March 19, 2011).
18. Joung, M.K., K.T. Kwon, C.I. Kang, H.S. Cheong, J.Y. Rhee, D.S. Jung, S.M. Chung, J.A. Lee, S.Y. Moon, K.S. Ko, D.R. Chung, N.Y. Lee, J.H. Song, and K.R. Peck. 2010. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J. Infect. 61:212-218.
19. Manchanda, V., S. Sanchaita, and N. Singh. 2010. Multidrug resistant acinetobacter. J. Glob. Infect. Dis. 2:291-304.
20. Mendes, R.E., D.J. Farrell, H.S. Sader, and R.N. Jones. 2010. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn. Microbiol. Infect. Dis. 68:307-311.
21. Pankey, G.A. 2005. Tigecycline. J. Antimicrob. Chemother. 56:470-480.
22. Poulakou, G., F.V. Kontopidou, E. Paramythiotou, M. Kompoti, M. Katsiari, E. Mainas, C. Nicolaou, D. Yphantis, A. Antoniadou, E. Trikka-Graphakos, Z. Roussou, P. Clouva, N. Maguina, K. Kanellakopoulou, A. Armaganidis, and H. Giamarellou. 2009. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J. Infect. 58:273-284.
23. Pugh, R.J., R.P. Cooke, and G. Dempsey. 2010. Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill. J. Hosp. Infect. 74:337-343.
24. Schafer, J.J., and D.A. Goff. 2008. Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev. Anti Infect. Ther. 6:557-567.
25. Song, J.Y., H.J. Cheong, W.S. Choi, J.Y. Heo, J.Y. Noh, and W.J. Kim. 2011. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J. Med. Microbiol. 60:605-611.
26. Tarchini, G. 2010. Tigecycline and bacteremia-the dangers of post hoc analysis of pooled data. Clin. Infect. Dis. 51:867-868; author reply 868.